CAN (Cardiac Autonomic Neuropathy)
Sort By:
PDi2
Detecting the 'Silent Killer' Cardiac Autonomic Neuropathy

Cardiac Autonomic Neuropathy occurs in 22% of Type 2 diabetics, and in 17% of Type 1 diabetics. 25–50% of patients exhibiting symptomatic autonomic neuropathy die within 5-10 years.

An estimated 60% of people with diabetes have some form of nerve damage or neuropathy. While diabetic neuropathy rarely involves the nerves of the brain or spine, signaling to and from other parts of the body can be impaired.
Nerves control everything from heartbeats to balance. The brain-to-heart signal processing forms a complex network which needs to accommodate for changes in activity and other bodily functions. Heart Rate Variability is a valid measure of Autonomic Nervous System health.

The PD2i AnalyzerTM readily allows for this assessment in the office setting.
Cardiac Autonomic Neuropathy in diabetes has been called a "silent killer", because so few patients realize that they suffer from it and yet its effect can be lethal.
Early detection of Cardiac Autonomic Neuropathy and intervention are of prime importance for risk stratification in preventing life threatening cardiac events. Analyzing Heart Rate Variability is a valuable tool in detecting autonomic neuropathy.

An Advance Over Conventional Diagnostics
Vicor’s PD2i®-based diagnostics offer several potential advantages over other measures.  They:

  •   are more predictive than competing tests
  •   are non-invasive
  •   may be performed by a nurse or technician
  •   are done at rest
  •   use inexpensive, non-proprietary ECG electrodes
  •   provide results in less than 20 minutes
  •   are easy to use
  •   yield a simple binary result
  •   are compact and portable
  •   are forgiving of data issues plaguing other diagnostics and are not derailed by irregular or ectopic beats
  •   may be performed on patients taking beta-blockers

Regulatory Status
Vicor’s PD2i Analyzer™ received FDA 510(k) marketing clearance to measure heart rate variability in early 2009; the use of heart rate variability measure is physician determined. Current procedural terminology (CPT) codes exist that enable physicians using the PD2i Analyzer™ to measure heart rate variability to be reimbursed by insurance carriers, creating a recurring source of revenue from test analysis for Vicor.

A Valuable Addition to Medical Practices
The PD2i Analyzer™ offers numerous advantages over competing diagnostics.  The PD2i Analyzer™:

  • provides better risk-stratification than conventional tests
  • is non-invasive
  • is performed on a resting patient by a nurse or technician
  • uses inexpensive, non-proprietary ECG electrodes
  • provides result in under 20 minutes
  • is easy to use; easy to interpret
  • yields a simple binary result
  • is compact (no treadmill required)
  • is forgiving of data issues plaguing other diagnostics
  • has a low up-front cost and low cost per-test

PD2i Analyzer  [ CAN ]
Call for pricing 800-452-8909
 
  
Sort By: